-冠状动脉无复流现象的防治.ppt

单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,冠状动脉无复流现象的防治,病人资料,毛某，男性，,78,岁，,糖尿病,8,年，高血压病，高脂血症，吸烟,20,余年，,1,年前戒除,主因发作性剑突下疼痛,4,天，于,2007,年,09,月,18,日由门诊以“冠心病 急性心肌梗死”收入科。,ECG,：,V1-V5,导联,ST,段抬高,0.2mv,。,肌钙蛋白升高。,CAG,CAG,球囊扩张前冠脉内给予硝酸甘油,200ug,，欣维宁,10ml,2.5*15mm,球囊扩张,球囊扩张后,植入支架,3.0*24mm,植入后造影,no-reflow,先后冠脉给予欣维宁再,10ml,、硝酸甘油,400ug,，异搏定,400ug,后,近端植入支架,3.5*14mm,植入后造影,no-reflow,再先后冠脉给予欣维宁,10ml,、硝酸甘油,500ug,，异搏定,600ug,后,一、无复流概述,无复流现象,(no-reflow),是指闭塞的心外膜冠状动脉再通后，心肌组织无灌注的现象。冠状动脉造影表现为血流明显减慢,(,血流,=,50%),或,ST,段抬高指数增加,(,=,30%),，对判断微血管灌注或无复流均有较高准确性,(81%),。,3,、心电图,经皮冠状动脉介入治疗后原病变部位无夹层、痉挛或阻塞而冠状动脉血流小于心肌梗死溶栓治疗临床试验,(TIMI)II级或心肌灌注,(TMP),血流分级,0-2,级，可以判定无复流。对于冠状动脉血流,TIMI III,级的病例，一部分表现为缓慢血流，另一部分为快血流，缓慢血流患者经超声、核素检查后仍可检出无复流病例，提示,TIMI,血流分级在判定无复流方面存在局限性。,4,、冠状动脉造影血流分级,在传统的,TIMI,血流分级法基础上用校正的,TIMI,帧数来评估微循环血流。这是一种较精确的识别技术，较传统的,TIMI,分级客观、定量、可重复、敏感。造影剂到达指定的冠状动脉远端所需的血管造影帧数越多，血流速度越慢，无复流存在的可能越大。,5,、校正的心肌梗死溶栓治疗临床试验帧数,(CTFC),采用多普勒血流导丝，进行血管内超声检查，测定时相性和平均冠状动脉血流速度；测定绝对冠状动脉血流储备,(CFR),指数，若显示冠状动脉血流储备指数下降，收缩期顺向血流速度下降，异常收缩早期逆向血流，舒张期血流速度迅速下降均提示无复流现象。收缩早期逆向血流是具有敏感性和特异性的评估无复流的指标。,6,、冠状动脉内多普勒血流,7,、超声心肌声学造影,(MCE),将声处理的造影物质,(,如氟丙烷白蛋白,),，其中含高能微泡，从冠状动脉或静脉途径注入，然后做心肌超声检查，受累区无复流灌注反应或心肌内气泡反常持续存在提示无复流现象。,目前由于声学造影剂的改进，二次谐波成像技术的应用和心肌声学造影分析方法的进步，心肌声学造影被认为是目前评估活体冠状动脉微循环异常的最有效方法之一。,8,、冠状动脉内压力测定,应用压力导丝测量靶动脉的压力阶差，并计算心肌血流储备分数,(,FFRmyo,),。当有微循环病变存在时，血流储备分数值会升高，此时还应当结合冠状动脉内血流储备分数进行判断。如果血流储备分数值较高而冠状动脉血流储备值低，说明有微血管功能障碍存在。,9,、其他方法,放射性核素运动心肌灌注显像、正电子发射断层和对比增强磁共振显像法，都可用于诊断无复流。,四、无复流的危险因素,PCI,术后是否发生无复流可根据临床特点、冠状动脉造影及冠状动脉内超声结果进行初步判断。,研究发现，,SVG PCI,时，血栓形成、,ACS,退化的静脉移植物、溃疡是发生低或无复流的,4,个独立危险因素，发生,SNR,的危险分别为：低危,(1%-10%)=3,个危险因素。,AMI PCI,时，,CAG,见高负荷的血栓形成是发生无复流现象的独立预测因素，表现为：,IRA,完全闭塞处呈切面残端、阻塞近端血栓,5mm,、浮动血栓存在、阻塞远端造影剂持续淤滞、参考管腔直径,(RLD)=4mm,、,II,型病变,(IRA,不完全阻塞性血栓长度超过,RLD3,倍,),。,IVUS,见到的有脂质池样图象的大血管也处于发生无复流的高危险。,相反，早期再灌注,=2,级、锥形阻塞，为不发生无复流的独立预测因素。,五、无复流的防治,预防,药物,远端保护/,血栓抽吸装置（主要用于桥血管,PCI,和,AMI,直接,PCI,）,直接支架植入,准分子激光消栓,药物,PCI,术前或术中冠状动脉内或外周静脉给药,硝酸甘油,（,Nitroglycerin,）,腺苷,（,Adenosine,）,尼可地尔,(K,ATP,通道开放剂,),（,Nicorandil,）,维拉帕米,（,Verapamil,）,地尔硫卓,（,Diltiazem,）,GP,IIb/IIIa,受体拮抗剂,（,GP,IIb/IIIa,receptor antagonist,）,等,均可减少无复流现象的发生。,维拉帕米,Early Administration of,Intracoronary,Verapamil,Improves Myocardial Perfusion During,Percutaneous,Coronary Interventions for Acute Myocardial Infarction,AMI,直接,PCI,前冠脉内给予维拉帕米改善心肌灌注,(CHEST 2005;128:25932598),目的：,To evaluate the effects of the administration of,intracoronary,verapamil,before the occurrence of no reflow during direct PCI.,50 patients ready to undergo direct PCI within 12 h from the onset of AMI,Intracoronary,verapamil,was administered immediately prior to balloon inflation,Had not received,intracoronary,calcium-channel blockers were enrolled as control subjects.,(CHEST 2005;128:25932598),(CHEST 2005;128:25932598),TMPG,：,TIMI myocardial perfusion grade,尼可地尔,Effects of Intravenous,Nicorandil,Before Reperfusion for Acute Myocardial Infarction in Patients With Stress Hyperglycemia,AMI,并应激性高血糖病人再灌注治疗前静脉注射尼可地尔的疗效,Diabetes Care,29:202206,2006,METHODS,：,This study consisted of 158 consecutive first AMI patients with stress hyperglycemia who underwent PCI within 24 h from the onset.They were randomly assigned to receive 12 mg of,nicorandil,(,n=,81)or a placebo(,n,=77)intravenously just before reperfusion.,Stress hyperglycemia was defined as a blood glucose level 10,mmol/l,(180 mg/dl).,Diabetes Care,29:202206,2006,（,P=0.032,）,（,P=0.027,）,（,P=0.032,）,Diabetes Care,29:202206,2006,尼可地尔不同给药途径的疗效,Impact of,Nicorandil,to Prevent Reperfusion Injury in Patients With Acute Myocardial Infarction,Sigmart,Multicenter,Angioplasty Revascularization Trial(SMART),Circ J 2006;70:1099 1104),90,个,AMI,起病,6,小时内的住院病人，,PCI,前,TIMI,血流,0-1,级。,随机分为,A,、,B,、,C 3,组，,A,组：尼可地尔,0.5 mg/,次，,PCI,前和后,1-2,次冠脉注射,(,总量原则上,1-2 mg),。,B,组：将尼可地尔配成,1 mg/ml.,先静脉推注,4 mg,，然后,6ml/h,静脉输注，加上,A,组方案冠脉内给药。,C,组：无药组,Circ J 2006;70:1099 1104),Circ J 2006;70:1099 1104),Fig 1.Primary endpoint.*p,50%,并为心绞痛罪犯血管的患者，随机分为,PCI,术中使用,Guardwire,Plus,的远端球囊阻塞,/,血栓抽吸装置组（N=406,）和传统,0.014 inch,导丝组（,N=395,）,主要终点：,30,天内死亡、心肌梗死、急诊搭桥或靶病变再血管成形术的联合终点。,Circulation.2002;105:1285-1290.),Circulation.2002;105:1285-1290.),(,P=,0.004),（,P=,0.008),（,P=,0.02),The Distal Protection During Primary,Percutaneous,Coronary Intervention Alleviates the Adverse Effects of Large Thrombus Burden on Myocardial Reperfusion,远端保护对大血栓负荷直接,PCI,心肌再灌注的影响,Circ J 2006;70,:,232 238,88 consecutive patients undergoing DP during primary PCI within 24 h from the onset of AMI were enrolled in the study(DP group).,81 consecutive patients undergoing primary PCI without using the DP device for AMI during the preceding 1 year(control group).,Circ J 2006;70,:,232 238,The,GuardWire,Plus(Medtronic)consists of a 0.014-inch,guidewire,incorporating a central inflation lumen to which an,elastomeric,balloon(3.06.0 mm in diameter),Circ J 2006;70,:,232 238,Circ J 2006;70,:,232 238,P,0.05,Circ J 2006;70,:,232 238,Circ J 2006;70,:,232 238,P0.05,Limitations of using a,GuardWire,temporary occlusion and aspiration system in patients with acute myocardial infarction:,multicenter,investigation of coronary artery protection with a distal occlusion device in acute myocardial infarction(MICADO).,J-Invasive-Cardiol.2007 Mar;19(3):132-8,MICADO,The study was conducted as a prospective,，,randomized,，,multicenter,trial.,This study evaluated the efficacy of distal protection with the,GuardWire,distal protection device in PCI at the time of AMI revascularization.,Patients with AMI within 24 hours from onset were randomized into either PCI combined with a,GuardWire,，,or PCI without distal protection.,The primary endpoints were TIMI perfusion grade(TMP)and no incidence of reflow.,Secondary endpoints were major cardiac events(MACE)during 6-month follow up.,J-Invasive-Cardiol.2007 Mar;19(3):132-8,J-Invasive-Cardiol.2007 Mar;19(3):132-8,（,p=0.054,）,MACE was observed in similar incidences between the two groups after 6-month follow up,X-,Sizer,机械血栓抽吸装置,Incidence,predictors,and outcomes of device failure of X-,sizer,thrombectomy,:Real-world experience of 200 cases in 5 years,Am Heart J 2007;153:14.e13-14.e19.Am Heart J 2007;153:14.e13-14.e19.,Am Heart J 2007;153:14.e13-14.e19.,Am Heart J 2007;153:14.e13-14.e19.,直接支架植入,A Randomized Comparison of Direct,Stenting,With Conventional,Stent,Implantation in Selected Patients With Acute Myocardial Infarction,AMI,直接支架植入和传统支架植入的随机对照研究,J Am,Coll,Cardiol,2002;39:1521,randomized,single-center trial,206 were allocated to direct,stent,implantation(n=102)or,stent,implantation after balloon pre-dilation(n=104),J Am,Coll,Cardiol,2002;39:1521,J Am,Coll,Cardiol,2002;39:1521,J Am,Coll,Cardiol,2002;39:1521,两组住院期间的临床结果,准分子激光消栓,Excimer,laser thrombus elimination for prevention of distal,embolization,and no-reflow in patients with acute ST elevation myocardial infarction,Results from the randomized Laser AMI study,27 consecutive patients with ST-segment elevation AMI(aged 57.89.2 years)were randomized either to balloon angioplasty and,stent,implantation alone(n=13)or adjunct ELCA(n=14).,International Journal of Cardiology 116(2007)2026,ELCA was feasible and safe in all cases.No procedure-associated complications were observed.,International Journal of Cardiology 116(2007)2026,P0.05,International Journal of Cardiology 116(2007)2026,International Journal of Cardiology 116(2007)2026,治疗,硝酸甘油,（,Nitroglycerin,）,腺苷,（,Adenosine,）,尼可地尔,(K,ATP,通道开放剂,),（,Nicorandil,）,维拉帕米,（,Verapamil,）,地尔硫卓,（,Diltiazem,）,硝普钠,（,Sodium,Nitroprusside,）,乌拉地尔,（,Urapidil,）,GP,IIb/IIIa,受体拮抗剂,（,GP,IIb/IIIa,receptor antagonist,）,Intracoronary,Verapamil,for Reversal of No-Reflow During Coronary Angioplasty for Acute Myocardial Infarction,冠脉内给予维拉帕米逆转,AMI,冠状动脉成形术中无复流,Cathet,Cardiovasc,Intervent,002;57:444451.,a consecutive series of 212 direct or rescue,PTCAs,for AMI,，,a TIMI flow grade 3 was observed in 23 patients(10.8%),Ten of the 23 patients had received GP,IIb/IIIa,antagonists before PTCA,Cathet,Cardiovasc,Intervent,002;57:444451.,A,：,LAD,闭塞，,B,：球囊扩张后,TIMI2,级血流，,C,：支架植入后无血流，,D,：沿导丝送入灌注导管至支架远端，注入维拉帕米,1mg,，,E,：保留灌注导管造影,TIMI3,级，,F,：,15MIN,后造影,Cathet,Cardiovasc,Intervent,002;57:444451.,Individual changes of TFC in 23 patients with no-reflow after,intracoronary,verapamil,.The significant change of group mean,standard deviation is also shown(,P,0.001).,Cathet,Cardiovasc,Intervent,002;57:444451.,Cathet,Cardiovasc,Intervent,002;57:444451.,腺甘和钙桔抗剂的实验对比研究,Cardiovasc,Drugs,Ther,(2006)20:167175,结扎区域,(LA),，,无复流区域,(ANR),，,坏死区域,(NA),Histopathological,组织病理学,